Factors previously reported to be independently associated with increased risk of recurrent VTE in patients with cancer-associated VTE
| Study . | Clinical factor or biomarker . | Estimated risk (95% CI) . |
|---|---|---|
| Prandoni et al, 20024 | Extensive cancer | HR: 4.6 (2.3-9.0)* |
| Lung cancer | HR: 6.9 (3.0-15.9)* | |
| Gastrointestinal cancer† | HR: 5.1 (2.3-11.3)* | |
| Genitourinary cancer‡ | HR: 3.7 (1.7-8.0)* | |
| Trujillo-Santos et al, 20085 | Age < 65 y | OR: 3.0 (1.9-4.9) for rPE |
| OR: 1.6 (1.0-2.4) for rDVT | ||
| Diagnosis < 3 mo earlier | OR: 2.0 (1.2-3.2) for rPE | |
| OR: 2.4 (1.5-3.6) for rDVT | ||
| Clinically overt PE | OR: 1.9 (1.2-3.1) | |
| Louzada et al, 201123 | Metastatic cancer | RR: 1.36 (1.06-1.74) |
| Chee et al, 201410 | Stage IV pancreatic cancer | HR: 6.38 (2.69-15.13) |
| Brain cancer | HR: 4.57 (2.07-10.09) | |
| MPN or MDS | HR: 3.49 (1.59-7.68) | |
| Ovarian cancer | HR: 3.22 (1.57-6.59) | |
| Stage IV (nonpancreas) cancer | HR: 2.85 (1.74-4.67) | |
| Lung cancer | HR: 2.73 (1.63-4.55) | |
| Neurological disease with leg paresis | HR: 2.38 (1.14-4.97) | |
| Cancer stage progression | HR: 2.14 (1.30-3.52) | |
| Mahé et al, 201711 | Lung cancer | HR: 3.8 (2.6-5.6)§ |
| Khorana et al, 201726 | Hepatobiliary cancer | sHR: 5.5 (2.3-13.6) |
| Venous compression | sHR: 3.1 (1.4-6.5) | |
| Tissue factor antigen | sHR: 3.3 (1.7-6.4) | |
| C-reactive protein | sHR: 1.9 (0.97-3.8) |
| Study . | Clinical factor or biomarker . | Estimated risk (95% CI) . |
|---|---|---|
| Prandoni et al, 20024 | Extensive cancer | HR: 4.6 (2.3-9.0)* |
| Lung cancer | HR: 6.9 (3.0-15.9)* | |
| Gastrointestinal cancer† | HR: 5.1 (2.3-11.3)* | |
| Genitourinary cancer‡ | HR: 3.7 (1.7-8.0)* | |
| Trujillo-Santos et al, 20085 | Age < 65 y | OR: 3.0 (1.9-4.9) for rPE |
| OR: 1.6 (1.0-2.4) for rDVT | ||
| Diagnosis < 3 mo earlier | OR: 2.0 (1.2-3.2) for rPE | |
| OR: 2.4 (1.5-3.6) for rDVT | ||
| Clinically overt PE | OR: 1.9 (1.2-3.1) | |
| Louzada et al, 201123 | Metastatic cancer | RR: 1.36 (1.06-1.74) |
| Chee et al, 201410 | Stage IV pancreatic cancer | HR: 6.38 (2.69-15.13) |
| Brain cancer | HR: 4.57 (2.07-10.09) | |
| MPN or MDS | HR: 3.49 (1.59-7.68) | |
| Ovarian cancer | HR: 3.22 (1.57-6.59) | |
| Stage IV (nonpancreas) cancer | HR: 2.85 (1.74-4.67) | |
| Lung cancer | HR: 2.73 (1.63-4.55) | |
| Neurological disease with leg paresis | HR: 2.38 (1.14-4.97) | |
| Cancer stage progression | HR: 2.14 (1.30-3.52) | |
| Mahé et al, 201711 | Lung cancer | HR: 3.8 (2.6-5.6)§ |
| Khorana et al, 201726 | Hepatobiliary cancer | sHR: 5.5 (2.3-13.6) |
| Venous compression | sHR: 3.1 (1.4-6.5) | |
| Tissue factor antigen | sHR: 3.3 (1.7-6.4) | |
| C-reactive protein | sHR: 1.9 (0.97-3.8) |
HR, hazard ratio; MPN, myeloproliferative neoplasm; MDS, myelodysplastic syndrome; OR, odds ratio; RR, relative risk; sHR, subdistrubutional hazard ratio; rDVT, recurrent deep vein thrombosis; rPE, recurrent pulmonary embolism.
Compared with patients without cancer.
Colorectal, stomach or esophagus, pancreas, liver, or gallbladder.
Uterus, kidney, ovary or testicle, bladder, prostate.
Compared with patients with breast cancer.